JPMorgan has increased its price target for Eli Lilly to $1,650, driven by upward revisions to 2026 and 2027 revenue and EPS forecasts. This reflects strong performance in Eli Lilly's metabolic business and weight-loss drug pipeline, with significant growth projected for incretin-related revenue by 2030.
JPMorgan raised its price target on Eli Lilly to $1,650, signaling increased confidence in the company's long-term earnings potential. This positive outlook is primarily driven by the robust performance of Eli Lilly's metabolic business and its promising weight-loss drug pipeline, leading to upward revisions in revenue and EPS forecasts for 2026 and 2027. The firm projects substantial growth in incretin-related revenue, reaching $110 billion by 2030, which is a significant long-term driver. For traders, this implies a positive short-term sentiment boost for LLY, with the long-term opportunity stemming from sustained growth and operating leverage as revenue expands and costs are diluted.